ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2016349-53ometendo-7823Research ArticleНаучные исследованияOriginal studiesПовышение уровня эндотелиального моноцитактивирующего пептида-II в сыворотке крови больных артериальной гипертензией в сочетании с сахарным диабетом 2-го типа и ожирениемAn elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesityМогильницькаяЛилия АнатольевнаMogylnytskaLiliya

кандидат мед. наук, врач-эндокринолог эндокринологического отделения

MD, PhD, endocrinologyst

mogylnytska@mail.uaМаньковскийБорис НикитичMankovskyBoris

член.кор. НАН и АМН Украины, доктор мед.наук

MD, PhD, prof.

mankovsky1964@yahoo.comХмельницкая обласна больницаУкраинаKhmelnytsky regional hospital, UkraineUkraineНациональная медицинская академия последипломного образования им.П.Л.Шупика, кафедра диабетологииУкраинаP.L. Shupyk National Medical Academy of Postgraduate EducationUkraine2016080720161334953Copyright © Могильницькая Л.А., Маньковский Б.Н., 20162016Могильницькая Л.А., Маньковский Б.Н.Mogylnytska L., Mankovsky B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/7823

Изучали содержание эндотелиального моноцитактивирующего пептида-II (ЕМАР-II) в сыворотке крови пациентов с артериальной гипертензией. Обследованы 41 больной с артериальной гипертензией и сахарным диабетом, 18 – с артериальной гипертензией и ожирением, 9 – с артериальной гипертензией и нормальной массой тела, 18 – контроль. Выявлено повышение ЕМАР-II у пациентов с артериальной гипертензией и сахарным диабетом 2-го типа в сравнении с контролем (4,86±2,3 и 1,08±0,53нг/мл, соответственно, р<0,01), у лиц с артериальной гипертензией и ожирением в сравнении с контролем (2,92±1,42 и 1,08±0,53нг/мл соответственно, р<0,01), а также в группе с артериальной гипертензией и нормальной массой тела в сравнении с контролем (2,02±0,33 и 1,08±0,53 соответственно, р<0,01). Обнаружена прямая корреляция между содержанием ЕМАР-II и гликозилированого гемоглобина, глюкозы крови, уровнем инсулина, индексом НОМА, показателями липидного обмена, индексом массы тела (р<0,01). Эти изменения могут быть проявлением эндотелиальной дисфункции при данном патологическом состоянии. Гипергликемия, дислипидемия, инсулинорезистентность, ожирение могут оказывать влияние на повышение уровня ЕМАР-II.

Objectives

Objectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.

Materials and methods

Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients without diabetes, 9 non-obese hypertensive patients without diabetes, and 18 healthy control subjects.

Results

Results: We found an increased serum level of EMAP-II in hypertensive patients with type 2 diabetes compared to controls (4.86±2.3 and 1.08±0.53 ng/ml respectively, р<0.01), in hypertensive patients with obesity (2.92±1.42 ng/ml) compared to controls, and in non-obese hypertensive patients (2.02±0.33 ng/ml) compared to controls. Also, the levels of EMAP-II significantly correlated with HbA1c, blood glucose, serum insulin levels, HOMA, lipids, and body mass index (р<0.01).

Conclusions

Conclusions: The revealed changes could reflect an endothelial dysfunction mostly pronounced in patients with arterial hypertension, type 2 diabetes mellitus and obesity. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of EMAP-II.

эндотелиальный моноцитактивирующий пептид-IIэндотелиальная дисфункцияартериальная гипертензиясахарный диабетожирение.endothelial monocyte activating polypeptide IIEMAP-IIendothelial dysfunctionarterial hypertensiontype 2 diabetesobesityReferencesDanaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. The Lancet. 2011;377(9765):568-577. doi: 10.1016/s0140-6736(10)62036-3.Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. The Lancet. 2011;377(9765):568-577. doi: 10.1016/s0140-6736(10)62036-3.Standards of Medical Care in Diabetes--2014. Diabetes Care. 2013;37(Supplement_1):S14-S80. doi: 10.2337/dc14-S014.Standards of Medical Care in Diabetes--2014. Diabetes Care. 2013;37(Supplement_1):S14-S80. doi: 10.2337/dc14-S014.Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906. doi: 10.1093/eurheartj/ehr211.Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906. doi: 10.1093/eurheartj/ehr211.DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nature Reviews Endocrinology. 2014;10(6):364-376. doi: 10.1038/nrendo.2014.44.DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nature Reviews Endocrinology. 2014;10(6):364-376. doi: 10.1038/nrendo.2014.44.Kang YS. Obesity Associated Hypertension: New Insights into Mechanism. Electrolytes & Blood Pressure. 2013;11(2):46. doi: 10.5049/ebp.2013.11.2.46.Kang YS. Obesity Associated Hypertension: New Insights into Mechanism. Electrolytes & Blood Pressure. 2013;11(2):46. doi: 10.5049/ebp.2013.11.2.46.Cremer A, Butlin M, Codjo L, et al. Determination of central blood pressure by a noninvasive method (brachial BP and QKD interval). J Hypertens. 2012;30(8):1533-1539. doi: 10.1097/HJH.0b013e328354dd26.Cremer A, Butlin M, Codjo L, et al. Determination of central blood pressure by a noninvasive method (brachial BP and QKD interval). J Hypertens. 2012;30(8):1533-1539. doi: 10.1097/HJH.0b013e328354dd26.Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association. 2001;285(19):2486-2497. doi: 10.1001/jama.285.19.2486.Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association. 2001;285(19):2486-2497. doi: 10.1001/jama.285.19.2486.van Horssen R, Eggermont AMM, ten Hagen TLM. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 2006;17(5):339-348. doi: 10.1016/j.cytogfr.2006.08.001.van Horssen R, Eggermont AMM, ten Hagen TLM. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 2006;17(5):339-348. doi: 10.1016/j.cytogfr.2006.08.001.Thompson JL, Ryan JA, Barr ML, et al. Potential role for antiangiogenic proteins in the myocardial infarction repair process. J Surg Res. 2004;116(1):156-164. doi: 10.1016/j.jss.2003.06.001.Thompson JL, Ryan JA, Barr ML, et al. Potential role for antiangiogenic proteins in the myocardial infarction repair process. J Surg Res. 2004;116(1):156-164. doi: 10.1016/j.jss.2003.06.001.Yuan C, Yan L, Solanki P, et al. Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis. J Mol Cell Cardiol. 2015;79:224-231. doi: 10.1016/j.yjmcc.2014.11.021.Yuan C, Yan L, Solanki P, et al. Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis. J Mol Cell Cardiol. 2015;79:224-231. doi: 10.1016/j.yjmcc.2014.11.021.Tsai BM. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. AJP: Regulatory, Integrative and Comparative Physiology. 2004;287(4):R767-R771. doi: 10.1152/ajpregu.00248.2004.Tsai BM. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. AJP: Regulatory, Integrative and Comparative Physiology. 2004;287(4):R767-R771. doi: 10.1152/ajpregu.00248.2004.Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol. 2014;63(25):2935-2959. doi: 10.1016/j.jacc.2013.11.005.Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol. 2014;63(25):2935-2959. doi: 10.1016/j.jacc.2013.11.005.Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2013;31(10):1925-1938. doi: 10.1097/HJH.0b013e328364ca4c.Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2013;31(10):1925-1938. doi: 10.1097/HJH.0b013e328364ca4c.Tocci G, Ferrucci A, Guida P, et al. An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Press Cardiovasc Prev. 2011;18(1):19-30. doi: 10.2165/11588040-000000000-00000.Tocci G, Ferrucci A, Guida P, et al. An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Press Cardiovasc Prev. 2011;18(1):19-30. doi: 10.2165/11588040-000000000-00000.Cockcroft J, Mancia G. Vascular aging. J Hypertens. 2012;30:S1-S2. doi: 10.1097/HJH.0b013e328353e4ec.Cockcroft J, Mancia G. Vascular aging. J Hypertens. 2012;30:S1-S2. doi: 10.1097/HJH.0b013e328353e4ec.Mohyl’nyts’ka LA. Serum Levels of Endothelial Monocyte-Activating Polypeptide-II in type 2 Diabetes Mellitus. Fiziol Zh. 2014;60(1):84-90.Mohyl’nyts’ka LA. Serum Levels of Endothelial Monocyte-Activating Polypeptide-II in type 2 Diabetes Mellitus. Fiziol Zh. 2014;60(1):84-90.Adly AAM, Ismail EA, Tawfik LM, et al. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine. 2015;76(2):156-162. doi: 10.1016/j.cyto.2015.06.006.Adly AAM, Ismail EA, Tawfik LM, et al. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine. 2015;76(2):156-162. doi: 10.1016/j.cyto.2015.06.006.Mauricio M, Aldasoro M, Ortega J, Vila J. Endothelial Dysfunction in Morbid Obesity. Curr Pharm Des. 2013;19(32):5718-5729. doi: 10.2174/1381612811319320007.Mauricio M, Aldasoro M, Ortega J, Vila J. Endothelial Dysfunction in Morbid Obesity. Curr Pharm Des. 2013;19(32):5718-5729. doi: 10.2174/1381612811319320007.Grossman E, Messerli FH. Hypertension and diabetes. AdvCardiol 2008; 45: 82-106. doi: 10.1159/0000115189Grossman E, Messerli FH. Hypertension and diabetes. AdvCardiol 2008; 45: 82-106. doi: 10.1159/0000115189Bornfeldt Karin E, Tabas I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metab. 2011;14(5):575-585. doi: 10.1016/j.cmet.2011.07.015.Bornfeldt Karin E, Tabas I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metab. 2011;14(5):575-585. doi: 10.1016/j.cmet.2011.07.015.Martín-Timón I. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444. doi: 10.4239/wjd.v5.i4.444.Martín-Timón I. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444. doi: 10.4239/wjd.v5.i4.444.

The authors declare that there are no conflicts of interest present.